Background Anti-SSA/Ro and anti-SSB/La antibodies are present in inflammatory autoimmune disease patient sera, and there are related to different clinical manifestations. It is well known the association between the presence of these antibodies in maternal blood and fetal atrioventricular block. However, there are no much studies about infertility or repeated abortions and anti-SSA/Ro and anti-SSB/La antibodies in broad series.
Objectives To characterise a cohort of patients with positive anti-SSA/Ro and/or anti-SSB/La antibodies and to evaluate the prevalence of abortions and neonatal mortality.
Methods Observational descriptive study with 162 patients older than 15 years old with pregnancies history and positive anti-SSA/Ro and/or anti-SSB/La antibodies from February 2011 to July 2015. We consider healthy women with pregnancies history and with comparable characteristics as negative control group.
Results We included 162 patients with positive anti-SSA/Ro and/or anti-SSB/La antibodies with a mean age of 50.5±14.2 years old. Main diagnosis were systemic lupus erythematosus (n=85), Sjögren syndrome (n=40), rheumatoid arthritis (n=16), systemic sclerosis (n=6), mixed connective tissue disease (n=3) and other diagnosis (n=12). Lupus anticoagulant was positive in 8 cases and 57 patients showed low complement values. 37% of patients had at least one pregnancy, and the 36.7% aborted during pregnancy.
There were no significant differences in the abortion incidence between our cohort of patients and the healthy control group considered.
We observed 4 cases of fetal atrioventricular block, all of them with positive anti-SSA/Ro and/or anti-SSB/La antibodies and only in one case also with positive lupus anticoagulant.
Conclusions In our series, pregnant women with positive anti-SSA/Ro and/or anti-SSB/La antibodies did not show high prevalence of abortion. However, the positivity of these antibodies was statistically correlated with the presence of fetal atrioventricular block.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.